Novel trans platinum complexes: Comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours

Anticancer Research

Volumn 16, Issue 1, 1996, Pages 33-38

  Goddard, Phyllis M ^a   Orr, Rosanne M ^a   Valenti, Melanie R ^a   Barnard, Christopher F J ^b   Murrer, Barry A ^b   Kelland, Lloyd R ^a   Harrap, Kenneth R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b JOHNSON MATTHEY TECHNOLOGY CENTRE   (United Kingdom)

Author keywords

Murine; Platinum; Trans; Tumours

Indexed keywords

CARBOPLATIN; CIS AMMINEDICHLORO(CYCLOHEXYLAMINE)DIHYDROXOPLATINUM; CISPLATIN; IPROPLATIN; MELPHALAN; PLATINUM AMMINE CYCLOHEXYLAMINE DICHLORIDE; PLATINUM DERIVATIVE; TETRAPLATIN; TRANS AMMINEDICHLORO(CYCLOHEXYLAMINE)DIHYDROXOPLATINUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; CROSS RESISTANCE; DRUG ACTIVITY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA; MOUSE; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TUMOR RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ISOMERISM; LEUKEMIA L1210; MICE; ORGANOPLATINUM COMPOUNDS; PLASMACYTOMA; TUMOR CELLS, CULTURED;

EID: 0029872331     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Loehrer PJ, Einhorn LH: Cisplatin. Ann Intern Med 100: 704-713, 1984.
2. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, Van Oosterom AT, Willemse PHB, Vermorken JB, van Lindert ACM, Heintz APM, Aartsen E, van Lent M, Trimbos JB, de Meijer AJ: Long-term survival in ovarian cancer. Eur J Cancer 27: 1367-1372, 1991.
3. Taylor AE, Wiltshaw E, Gore ME, Fryatt I, Fisher C: Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 12. 2066-2070, 1994.
4. Kelland LR: New platinum antitumor complexes. Crit Rev Oncol Hematol 15: 191-219, 1993.
5. Connors TA, Cleare MJ, Harrap KR: Structure-activity relationships of the antitumor platinum coordination complexes. Cancer Treat Rep 63: 1499-1502, 1979
6. Farrell N, Kelland LR, Roberts JD, Van Beusichem M: Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands, in murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Res 52: 5065-5072, 1992
7. Van Beusichem M, Farrell N: Activation of the trans geometry in platinum antitumor complexes. Synthesis, characterization, and biological activity of complexes with the planar ligands pyridine, N-methylimidazole, thiazole and quinoline. Crystal and molecular structure of trans-dichlorobis(thiazole)platinum(II). Inorg Chem 31: 634-639, 1992.
8. Coluccia M, Nassi A, Loseto F, Boccarelli A, Mariggio MA, Giordano D, Intini FP, Caputo P, Natile G: A trans-platinum complex showing higher antitumor activity than the Cis congeners. J Med Chem 36: 510-512, 1993.
9. Kelland LR, Barnard CFJ, Mellish KJ, Jones M, Goddard PM, Valenti M, Bryant A, Murrer BA, Harrap KR: A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity. Cancer Res 54: 5618-5622, 1994.
10. Kelland LR, Barnard CFJ, Evans IG, Murrer BA, Theobald BRC, Vaughan OJ, Wyer SB, Goddard PM, Jones M, Valenti M, Bryant A, Rogers PM, Harrap KR: Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes. J Med Chem 38: 3016-3024, 1995.
11. Nicolson MC, Orr RM, O'Neill CF, Harrap KR: The role of platinum uptake and glutathione levels in L1210 cells sensitive and resistant to cisplatin, tetraplatin or carboplatin. Neoplasma 39: 189-195, 1992.
12. Orr RM, O'Neill CF, Nicolson MC, Barnard CF, Murrer BA, Giandomenico CM, Vollano JF, Harrap KR: Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin. Br J Cancer 70: 415-420, 1994
13. Goddard PM, Valenti MR, Harrap KR: The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: a cautionary note. Ann Oncol 2: 535-540, 1991.
14. Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR: Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 53: 2581-2586, 1993.
15. Harrap KR: Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 12: 21-33, 1985.
16. Burchenal JH, Irani G, Kern K, Lokys L, Turkevich J: 1,2-diaminocyclohexane platinum derivatives of potential clinical value. Rec Res Cancer Res 74: 146-155, 1980.
17. Mellish KJ, Barnard CFJ, Kelland LR, Harrap KR: Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine(cyclohexylamine) dichloro dihydroxo platinum(IV)]. Int J Cancer 59:65-70, 1994.
18. Mellish KJ, Barnard CFJ, Murrer BA, Kelland LR: DNA binding properties of novel cis- and trans platinum-based anticancer agents in two human ovarian carcinoma cell lines. Int J Cancer 62: 717-723, 1995
19. Goddard P, Valenti M, Kelland LR: The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts. Anticancer Res 14: 1065-1070, 1994.